Stifel lifts target for IQVIA Holdings stock to USD 303.00
Published on 10/15/2026 at 22:09 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWSAnalyst target and reporting date
- Stifel raised its IQVIA target from USD 276.00 to USD 303.00 on October 14, 2026.
- IQVIA will announce third-quarter 2026 results on October 27, 2026.
- IQVIA Holdings stock costs EUR 241.40 at Lang & Schwarz on October 15, 2026 at 10:06 p.m. CEST, 2.64 percent above the Xetra close of October 13, 2026.
- IQVIA had a market capitalization of USD 44.6 billion and a price-to-earnings ratio of 33.65 on October 15, 2026.
Stifel raised its IQVIA Holdings price target from USD 276.00 to USD 303.00 on October 14, 2026, while maintaining its Buy rating, according to Investing.com. The new target is 11.71 percent above the USD 271.25 NYSE price last quoted on October 15, 2026 at 3:59 p.m. ET. IQVIA Holdings stock was trading at EUR 241.40 at Lang & Schwarz on October 15, 2026 at 10:06 p.m. CEST, 2.64 percent above the Xetra close of October 13, 2026 at EUR 235.20.
Results date brings the next test
IQVIA will announce its third-quarter 2026 results before the US market opens on October 27, 2026, according to the company's investor-relations release dated September 29, 2026, which also scheduled a 9:00 a.m. ET conference call. The date gives the market a clear near-term event after the recent analyst revisions. IQVIA said the release would be published before the opening bell.
Price position after the latest move
The euro quote sits EUR 35.65 below the 52-week high of EUR 277.05 and EUR 86.90 above the 52-week low of EUR 154.50. The primary-market range in USD runs from USD 154.50 to USD 277.40, placing the NYSE price of USD 271.25 near the upper end on October 15, 2026. Trading volume was 963,796 shares against an average volume of 1,451,009 shares.
Valuation and upcoming numbers
IQVIA had a market capitalization of USD 44.6 billion and a price-to-earnings ratio of 33.65 on October 15, 2026. The second-quarter 2026 report showed revenue of USD 4.37 billion, operating profit of USD 506.0 million and diluted earnings per share of USD 1.53. Revenue was USD 4.15 billion in the first quarter of 2026, making the second-quarter increase USD 217.0 million, or 5.23 percent quarter over quarter.
Comparison with peers
IQVIA Holdings (NYSE, USD): plus 3.53 percent, price-to-earnings ratio 33.65, market capitalization USD 44.6 billion
Thermo Fisher Scientific (NYSE, USD): plus 2.06 percent, price-to-earnings ratio 33.00, market capitalization USD 231.0 billion
Danaher (NYSE, USD): plus 1.66 percent, price-to-earnings ratio 38.00, market capitalization USD 147.0 billion
What the price now measures
The market is balancing a higher Stifel target against the next earnings date and the stock's position near its yearly high. The valuation figures and the October 27 reporting date make the upcoming results the next measurable test for the current price.
The further course of trading is shown by the continuously updated real-time quote of IQVIA Holdings stock.
IQVIA Holdings stock at a glance
- Company: IQVIA Holdings Inc.
- ISIN: US46266C1053
- Ticker: IQV
- Primary exchange: NYSE
- Price Lang & Schwarz as of October 15, 2026, 10:06 p.m. CEST: EUR 241.40
- Change versus Xetra close: plus 2.64 percent
- Xetra close October 13, 2026: EUR 235.20
- Market capitalization: USD 44.6 billion (as of October 15, 2026)
- 52-week range: USD 154.50-277.40 (as of October 15, 2026)
- Sector / Industry: Healthcare / Medical Diagnostics and Research
- Next earnings date: October 27, 2026
Market context: Market report S&P 500.
